B Cell Lymphoma
From the Journals
Pembrolizumab shows promise for relapsed/refractory PMBCL
The findings raise the question of whether PD-1 blockade could resensitize tumors to chemotherapy.
Perspectives
Primary CNS lymphoma: R-CHOP hits back
Twenty years after it was concluded that there was no role for R-CHOP in the treatment of primary CNS lymphoma, researchers are reconsidering that...
Conference Coverage
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.
From the Journals
Ibrutinib linked to hypertension in B-cell malignancies
New or worsening hypertension was also linked with a greater risk of major adverse cardiac events.
From the Journals
Best treatment approach for early stage follicular lymphoma is unclear
Overall survival rates were similar with different treatment approaches, including watchful waiting.
From the Journals
Follow-up shows favorable results with acalabrutinib in MCL
The median duration of response exceeded 2 years with acalabrutinib monotherapy.
Conference Coverage
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
Decoding biosimilar approvals
SAN FRANCISCO – Regulators must consider several factors when expanding the use of an approved biosimilar from one indication to another, based on...
Conference Coverage
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
Conference Coverage
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
Conference Coverage
GALACTIC CLL trial: Obinutuzumab consolidation helps eradicate MRD
EDINBURGH – Obinutuzumab consolidation after chemoimmunotherapy for B-CLL was highly effective for eradicating MRD within 6 months post...